Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Multiple sclerosis

Current treatment strategies to halt progression.

    • Education
    • Neurology
    • Rheumatology
    • RX
    • Studies
  • 3 minute read

In most cases, multiple sclerosis is relapsing and can progress to a chronic progressive stage over time. Which therapy management is used depends not only on the individual circumstances but also essentially on the efficacy, safety and tolerability of the treatment. However, effective therapies for progressive forms are limited.

The options for course-modifying treatment in progressive multiple sclerosis (MS) are currently still limited compared to the relapsing form of the disease. This is because, in addition to inflammation, neurodegeneration in the central nervous system also plays a role. These are associated with progression, irreversible deterioration occurring independently of relapses. Approximately half of patients progress from relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS) after 15-20 years of disease progression. In about 15% of affected individuals, a gradually progressive, primary progressive form of MS (PPMS), in which no relapses occur, is already evident at the beginning. The progression of the disease can then be more rapid than in a relapsing course. But effective treatment options are rare.

Many of the treatment options established in RRMS have not been found to be equally effective in SPMS. In addition to glatiramer acetate and fingolimod, these include natalizumab and cladribine [1–4]. However, other less established immunomodulatory or immunosuppressive agents have also failed to demonstrate convincing efficacy in progressive MS [5]. Currently, there are only four substances available in Switzerland for MS patients with a progressive form. In addition to interferon beta-1b, mitoxantrone, and ocrelizumab, siponimod was approved in SPMS in late 2020. This is a further development of fingolimod and binds selectively to receptor subtypes 1 and 5. In the pivotal study, a significant reduction in the risk of disability progression at three and six months was demonstrated compared to placebo – independent of relapses [6]. There was also less inflammatory activity on MRI and less loss of brain volume.

SPMS in focus

One of the few substances that can be used in both RRMS and SPMS is interferon beta-1b. In a placebo-controlled study, a significant treatment effect was shown with respect to disability progression after at least two years of treatment [7]. In contrast, a large Cochrane meta-analysis found no effect on clinical disease progression [8]. The experts therefore tend to assume a minor effect on progression.

Third in the group is the cytostatic drug mitoxantrone, which has an immunomodulatory effect. Following individual cases and observations, a placebo-controlled study was conducted that demonstrated a significant difference in the number of relapses and clinical disability after two years [9]. Approval in Switzerland is limited to ambulatory patients with rapidly progressive disease or after failure or intolerance of other immunomodulators.

Monoclonal antibody in PPMS

The only agent approved for PPMS is ocrelizumab, a monoclonal antibody. It is directed against the differentiation antigen CD20 and leads to effective prolonged depletion of lymphocytes, especially B cells [10]. A large phase III trial demonstrated a significantly lower risk of 24 and 25% for disability progression at three and six months, respectively, compared with placebo [11]. In addition, it resulted in a smaller total volume of T2-hypertensive MRI lesions and a smaller decrease in brain volume. There was also a positive effect on walking ability and upper extremity function.

 

Literature:

  1. Wolinsky JS, Narayana PA, O’Connor P, et al: Ann Neurol 2007; 61: 14-24.
  2. Lublin F, Miller DH, Freedman MS, et al: Lancet 2016; 387: 1075-1084.
  3. Kapoor R, Ho PR, Campbell N, et al: The Lancet Neurology 2018; 17: 405-415.
  4. Sipe J: The Lancet 1994; 344: 9-13.
  5. Filippini G, Del Giovane C, Vacchi L, et al: Available at: http://doi.wiley.com/10.1002/14651858.CD008933.pub.2
  6. Kappos L, Bar-Or A, Cree BAC, et al: Lancet 2018; 391: 1263-1273.
  7. Kappos L, Polman C, Pozzili C, et al: Neurology 2004; 57: 1969-1975.
  8. La Mantia L, Vacchi L, Di Pientrantonj C, et al: Available at: http://doi.wiley.com/10.1002/14651858CD005181.pub.3
  9. Hartung HP, Gonsette R, König N, et al: Lancet 2002; 360: 2018-2025.
  10. Graf J, Albrecht P, Goebels N, et al: The Neurologist 2020; 91: 722-734.
  11. Hauser SL, Bar-Or A, Comi G, et al: N Engl J Med 2017; 376: 221-234.

 

InFo NEUROLOGY & PSYCHIATRY 2021; 19(1): 18.

Autoren
  • Leoni Burggraf
Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
  • MS
  • Multiple sclerosis
  • ppms
Previous Article
  • The somewhat different knowledge

Where does the name “Pancoast tumor” actually come from?

  • Education
  • General Internal Medicine
  • Oncology
  • Pneumology
  • RX
View Post
Next Article
  • Lupus nephritis

Special case kidney

  • Congress Reports
  • Nephrology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 5 min
  • Asthma in adults

When do pneumology specialists come into play?

    • RX
View Post
  • 10 min
  • Cutaneous lupus erythematosus

From diagnostic workup to successful treatment

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.